Immunis.AI closes on funding for immunogenomic platform

By staff writers

October 1, 2021 -- Immunis.AI recently closed on additional financing that brings its total raised to $40 million to date for the ongoing development of its immunogenomic platform.

The company said the funding will support further validation and commercialization of the company's prostate cancer molecular test and will expand development of new tests in breast, colon, lung cancer, and other cancers.

Copyright © 2021

Last Updated ls 10/1/2021 10:09:36 AM